Faron Pharmaceuticals Oy FARON.HE Stock
Faron Pharmaceuticals Oy Price Chart
Faron Pharmaceuticals Oy FARON.HE Financial and Trading Overview
| Faron Pharmaceuticals Oy stock price | 1.55 EUR |
| Previous Close | 3.1 EUR |
| Open | 3.1 EUR |
| Bid | 3.07 EUR x N/A |
| Ask | 3.14 EUR x N/A |
| Day's Range | 3.1 - 3.15 EUR |
| 52 Week Range | 1.84 - 4.97 EUR |
| Volume | 1.39K EUR |
| Avg. Volume | 11.57K EUR |
| Market Cap | 199.7M EUR |
| Beta (5Y Monthly) | 0.067816 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.48 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
FARON.HE Valuation Measures
| Enterprise Value | 187.19M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 248.69275 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 233.114 |
| Enterprise Value/EBITDA | -6.86 |
Trading Information
Faron Pharmaceuticals Oy Stock Price History
| Beta (5Y Monthly) | 0.067816 |
| 52-Week Change | 18.32% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 4.97 EUR |
| 52 Week Low | 1.84 EUR |
| 50-Day Moving Average | 3.42 EUR |
| 200-Day Moving Average | 3.12 EUR |
FARON.HE Share Statistics
| Avg. Volume (3 month) | 11.57K EUR |
| Avg. Daily Volume (10-Days) | 10.19K EUR |
| Shares Outstanding | 63.5M |
| Float | 33.79M |
| Short Ratio | N/A |
| % Held by Insiders | 45.14% |
| % Held by Institutions | 13.47% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -3415.31% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -140.19% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 803K EUR |
| Revenue Per Share (ttm) | 0.02 EUR |
| Quarterly Revenue Growth (yoy) | -86.90% |
| Gross Profit (ttm) | N/A |
| EBITDA | -27288000 EUR |
| Net Income Avi to Common (ttm) | -28730000 EUR |
| Diluted EPS (ttm) | -0.53 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 6.99M EUR |
| Total Cash Per Share (mrq) | 0.12 EUR |
| Total Debt (mrq) | 13.27M EUR |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.929 |
| Book Value Per Share (mrq) | -0.192 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -22993000 EUR |
| Levered Free Cash Flow (ttm) | -12454750 EUR |
Profile of Faron Pharmaceuticals Oy
| Country | Finland |
| State | N/A |
| City | Turku |
| Address | Joukahaisenkatu 6 B |
| ZIP | 20520 |
| Phone | 358 2469 5151 |
| Website | https://www.faron.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 40 |
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. It also develops Haematokine, an investigational AOC3 inhibitor that is used for regenerative medicines in hematological malignancies, as well as chemotherapy induced suppression of the bone marrow. In addition, the company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.
Q&A For Faron Pharmaceuticals Oy Stock
What is a current FARON.HE stock price?
Faron Pharmaceuticals Oy FARON.HE stock price today per share is 1.55 EUR.
How to purchase Faron Pharmaceuticals Oy stock?
You can buy FARON.HE shares on the Helsinki exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Faron Pharmaceuticals Oy?
The stock symbol or ticker of Faron Pharmaceuticals Oy is FARON.HE.
Which industry does the Faron Pharmaceuticals Oy company belong to?
The Faron Pharmaceuticals Oy industry is Biotechnology.
How many shares does Faron Pharmaceuticals Oy have in circulation?
The max supply of Faron Pharmaceuticals Oy shares is 69.41M.
What is Faron Pharmaceuticals Oy Price to Earnings Ratio (PE Ratio)?
Faron Pharmaceuticals Oy PE Ratio is now.
What was Faron Pharmaceuticals Oy earnings per share over the trailing 12 months (TTM)?
Faron Pharmaceuticals Oy EPS is -0.48 EUR over the trailing 12 months.
Which sector does the Faron Pharmaceuticals Oy company belong to?
The Faron Pharmaceuticals Oy sector is Healthcare.
Faron Pharmaceuticals Oy FARON.HE included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| First North All-Share SEK FIRSTNORTHSEK | 123.34 SEK 12.04 USD |
-0.14
|
— — | — — | — — | — - | — — |
| First North 25 FN25 | 2021.27 EUR 2209.52 USD |
-1.13
|
— — | — — | — — | — - | — — |
| First North All-Share EUR FIRSTNORTHEUR | 97.9 EUR 107.01 USD |
-0.64
|
— — | — — | — — | — - | — — |
- {{ link.label }} {{link}}